Research graph
References from Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Implications of subclinical tuberculosis for vaccine trial design and global effect
10.1016/s2666-5247(24)00127-7 · 2024 · External reference
End-point definition and trial design to advance tuberculosis vaccine development
10.1183/16000617.0044-2022 · 2022 · External reference
Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis
10.1056/nejmoa1803484 · 2018 · External reference
Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis
10.1056/nejmoa1909953 · 2019 · External reference
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials
10.1016/s2213-2600(25)00164-x · 2025 · External reference
Screening for asymptomatic tuberculosis among adults with household exposure to a patient with pulmonary tuberculosis
10.1016/s2214-109x(25)00276-1 · 2025 · External reference
Subclinical tuberculosis disease-a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology
10.1093/cid/ciaa1402 · 2021 · External reference
Whom tuberculosis tests detect and why it matters: implications for diagnostic algorithms
10.1016/j.lanmic.2025.101237 · 2025 · External reference
The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review
10.1080/21645515.2022.2027160 · 2022 · External reference
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
10.1016/s1473-3099(25)00536-5 · 2025 · External reference
Recurrent subclinical tuberculosis among antiretroviral therapy–accessing participants: incidence, clinical course, and outcomes
10.1093/cid/ciac185 · 2022 · External reference
Role of tuberculosis symptoms in transmission risk to cell contacts in prisons
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
External reference
Mind the gap – managing tuberculosis across the disease spectrum
10.1016/j.ebiom.2022.103928 · 2022 · External reference
Healthcare seeking patterns for TB symptoms: findings from the first national TB prevalence survey of South Africa, 2017–2019
10.1371/journal.pone.0282125 · 2023 · External reference
Reported tuberculosis symptoms: an inadequate classifier of disease state
10.1093/cid/ciaf611 · 2026 · External reference
Rapid molecular detection of tuberculosis and rifampin resistance
10.1056/nejmoa0907847 · 2010 · External reference
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
2014 · External reference
The new Xpert MTB/RIF ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing
10.1128/mbio.00812-17 · 2017 · External reference
Cumulative TB disease burden following sputum Xpert Ultra ‘Trace’ results in clinical settings: results from a multi-site observational clinical study
2025 · External reference
Pulmonary tuberculosis detection with MiniDock MTB using swab samples
10.1056/nejmoa2509761 · 2026 · External reference
Tongue swab Mycobacterium tuberculosis qPCR for community screening of asymptomatic TB vs. clinic-based triage of symptomatic TB
2026 · External reference
Diagnostic accuracy of swab-based molecular tests for tuberculosis using novel near point-of-care platforms: a multi-country evaluation
10.1016/j.ebiom.2025.105991 · 2025 · External reference
Novel near-point-of-care tuberculosis molecular tests: navigating the repercussions of sensitivity tradeoffs
10.5588/ijtld.25.0793 · 2026 · External reference
Diagnostic performance of the Pluslife MiniDock MTB and molbio MTB ultima assays to detect tuberculosis from tongue and sputum swabs among outpatients and in active case finding in Cameroon
2025 · External reference
Diagnostic accuracy of a novel point-of-care tongue swab assay for pulmonary tuberculosis: a multicentre prospective study
10.1016/j.cmi.2025.11.010 · 2026 · External reference
Reimagining the status quo: how close are we to rapid sputum-free tuberculosis diagnostics for all?
10.1016/j.ebiom.2022.103939 · 2022 · External reference
The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection
10.1017/s0950268897007917 · 1997 · External reference
Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise
10.1016/s2213-2600(24)00028-6 · 2024 · External reference
Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped
10.1097/qad.0000000000000278 · 2014 · External reference
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania
10.1086/429825 · 2005 · External reference
Present outlooks on the prevalence of minimal and subclinical tuberculosis and current diagnostic tests: a systematic review and meta-analysis
10.1016/j.jiph.2024.102517 · 2024 · External reference
Multicountry assessment of tongue swabs for tuberculosis using a common protocol for Xpert MTB/RIF Ultra testing: a prospective diagnostic accuracy study
10.1016/j.lanmic.2025.101330 · 2026 · External reference
Decentralized clinical trials and digital health technologies
2024 · External reference
Remote monitoring in clinical trials during the COVID-19 pandemic
10.1111/cts.12834 · 2020 · External reference
Rapid quantitative PCR on tongue swabs for pulmonary tuberculosis in adults: a prospective multicentre study
10.1183/13993003.01493-2024 · 2025 · External reference
10.1186/s12913-026-14974-5 · 2026 · Admitted local publication
Assessment of Minidock MTB for the diagnosis of tuberculosis from sputum in patients presenting to health facilities in Indonesia
2026 · External reference
WHO target product profile for TB detection at peripheral settings: 2024 update
2025 · External reference
Toward the development of a circulating free DNA-based in vitro diagnostic test for infectious diseases: a review of evidence for tuberculosis
10.1128/jcm.01234-18 · 2019 · External reference
Multigene Mycobacterium tuberculosis cell-free DNA assay
10.5588/ijtld.24.0353 · 2025 · External reference
Genome-wide tiled detection of circulating Mycobacterium tuberculosis cell-free DNA using Cas13
10.1038/s41467-023-37183-8 · 2023 · External reference
Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients
10.5588/ijtld.21.0055 · 2021 · External reference
Rapid tuberculosis diagnosis from respiratory or blood samples by a low cost, portable lab-in-tube assay
10.1126/scitranslmed.adp6411 · 2025 · External reference
Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional survey
10.1016/s1473-3099(22)00149-9 · 2022 · External reference
Precision-enhancing risk stratification tools for selecting optimal treatment durations in tuberculosis clinical trials
10.1164/rccm.202101-0117oc · 2021 · External reference
Capacity building in sub-Saharan Africa as part of the INTENSE-TBM project during the COVID-19 pandemic
2022 · External reference
A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay
10.1164/rccm.201103-0536oc · 2011 · External reference
Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression
10.1164/rccm.201312-2140oc · 2014 · External reference
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
10.1016/s1473-3099(17)30691-6 · 2018 · External reference
Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents
10.1111/j.1469-0691.2011.03626.x · 2012 · External reference
The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis
10.1016/s2213-2600(23)00097-8 · 2023 · External reference
Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies
10.1016/j.smim.2022.101672 · 2023 · External reference
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
10.1016/s0140-6736(20)32661-1 · 2021 · External reference
Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19
10.1056/nejmoa2101544 · 2021 · External reference
Efficacy and other milestones for human papillomavirus vaccine introduction
10.1016/j.vaccine.2004.07.046 · 2004 · External reference
